Figure 2: Clinical course of the patient. Day 1 is the day of starting intravenous immunoglobulin therapy. The neuropathy impairment score was based on a report by Dyck et al. [5] and was derived by summing the scores for cranial nerve impairment, muscle weakness, deep tendon reflex impairment, and sensory impairment. The degree of impairment was evaluated according to a 5-grade scale as follows: 0, no deficit; 1, mild deficit; 2, moderate deficit; 3, severe deficit; and 4, complete absence of function or severest deficit.